In Vivo Investigation of Cardiac Benefits of Sodium Glucose Cotransporter Inhibition Using the Zebrafish Model
| Author | Essa, Asma |
| Author | Aldous, Noura |
| Author | Benslimane, Fatiha |
| Author | Yalcin, Huseyin |
| Available date | 2020-10-26T08:49:56Z |
| Publication Date | 2020 |
| Publication Name | Qatar University Annual Research an Exhibition 2020 (quarfe) |
| Citation | Essa A., Aldous N., Benslimane F., Yalcin H., "In Vivo Investigation of Cardiac Benefits of Sodium Glucose Cotransporter Inhibition Using the Zebrafish Model", Qatar University Annual Research Forum and Exhibition (QUARFE 2020), Doha, 2020, https://doi.org/10.29117/quarfe.2020.0199 |
| Abstract | Type 2 diabetes mellitus (T2DM) affects >16% of adults in Qatar. Newly emerging class of antidiabetic drugs focuses on SGLT inhibition were observed to reduce CVDs risks in diabetic patients. Up to date, the mechanism contributing to the CV benefits remains unrevealed. Zebrafish embryos were injected with different morpholinos to knockdown SGLT genes and study their effects on cardiac parameters. SGLT1 inhibition caused the most severe effects on zebrafish embryos with survival rate ~10 %. It also caused tube-like structured heats with edema, affecting significantly the cardiac output and diameter, and increased cardiac markers expressions. Analysis acquired correlates with literature data of SGLT1 predominant expression in heart tissues |
| Language | en |
| Publisher | Qatar University Press |
| Subject | T2DM CVDs Zebrafish |
| Type | Poster |
Files in this item
This item appears in the following Collection(s)
-
Theme 2: Population, Health & Wellness [118 items ]